智通财经APP获悉，礼来(LLY.US)确认已同意以每股14美元的现金收购Ventyx Biosciences (VTYX.US)。 根据周三发布的一份声明，该交易的总股权价值约为 12 亿美元。该交易不附加任何融资条件，预计将 于今年上半年完成。美银证券担任礼来的独家财务顾问，杰富瑞担任Ventyx的首席财务顾问。 总部位于圣地亚哥的Ventyx专注于研发治疗克罗恩病和类风湿性关节炎等炎症性疾病的药物，礼来收购 该公司旨在拓展其在免疫学领域的业务。 与此同时，该公司正在寻求收购以扩充其产品线。2024年，该公司以32亿美元收购了Morphic Therapeutics，获得了一种用于治疗炎症性肠病的实验性药物。此外，该公司还斥资24亿美元收购了 Dice Therapeutics，后者是一家开发口服银屑病疗法的公司。 礼来公司表示，免疫学是其关键增长领域，该公司希望在糖尿病和肥胖症治疗领域取得巨大成功的基础 上，进一步拓展业务。这些成功吸引了投资者和患者的关注。该公司目前已销售多种治疗关节炎和银屑 病等炎症性疾病的药物，包括Taltz，但Taltz的关键专利保护将在未来几年内到期。 ...

Core Viewpoint - Ademi LLP is investigating Ventyx for potential breaches of fiduciary duty and other legal violations related to its transaction with Eli Lilly, which involves a cash offer of $14.00 per share, valuing the deal at approximately $1.2 billion [1][2]. Group 1: Transaction Details - Ventyx stockholders will receive $14.00 per share in an all-cash transaction valued at around $1.2 billion [2]. - The transaction agreement includes provisions that significantly limit competing offers for Ventyx, imposing penalties if a competing bid is accepted [3]. Group 2: Board Conduct and Shareholder Rights - The investigation focuses on the conduct of Ventyx's board of directors to determine if they are fulfilling their fiduciary duties to all shareholders [3]. - Ademi LLP specializes in shareholder litigation related to buyouts, mergers, and individual shareholder rights [4].

Ventyx's clinical pipeline includes multiple small molecules with potential for oral therapies addressing chronic inflammation INDIANAPOLIS, Jan. 7, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Ventyx Biosciences, Inc. (Nasdaq: VTYX), a San Diego-based clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with inflammatory-mediated diseases, today announced entry into a definitive agreement for Lilly to acquire Ventyx. Ventyx is developing a pipe ...

U.S. stocks were mixed, with the Dow Jones index falling around 0.2% on Wednesday.Shares of Monte Rosa Therapeutics Inc (NASDAQ:GLUE) rose sharply during Wednesday's session after the company announced interim data from an ongoing Phase 1 clinical study evaluating MRT-8102.Monte Rosa Therapeutics shares jumped 45.2% to $23.25 on Wednesday.Here are some other big stocks recording gains in today’s session.Ventyx Biosciences Inc (NASDAQ:VTYX) gained 37.5% to $13.82 following reports that Indianapolis-based Eli ...

此外，Ventyx的一款实验性药物目前正处于中期临床阶段，用于治疗一种与肥胖相关的心血管疾病，被 视为其管线中的重要潜力项目。 周三，Ventyx Biosciences(VTYX.US)股价暴涨，截至发稿，该股涨超37%，报13.79美元。据悉礼来 (LLY.US)接近达成以超10亿美元收购该公司的交易。若该交易达成，将为礼来在研管线新增炎症性肠病 相关药物，包括克罗恩病和溃疡性结肠炎治疗项目，同时还将补充帕金森病等疾病领域的研发资产。 ...

智通财经APP获悉，周三，Ventyx Biosciences(VTYX.US)股价暴涨，截至发稿，该股涨超37%，报13.79 美元。据悉礼来(LLY.US)接近达成以超10亿美元收购该公司的交易。若该交易达成，将为礼来在研管线 新增炎症性肠病相关药物，包括克罗恩病和溃疡性结肠炎治疗项目，同时还将补充帕金森病等疾病领域 的研发资产。 此外，Ventyx的一款实验性药物目前正处于中期临床阶段，用于治疗一种与肥胖相关的心血管疾病，被 视为其管线中的重要潜力项目。 ...

| 德国DAX30 | 25,034.13 | 25,098.63 | 24,975.49 | +137.19 | +0.55% | | --- | --- | --- | --- | --- | --- | | 器 英国富时100 | 10,056.68 | 10,107.40 | 10,047.25 | -66.05 | -0.65% | | II 法国CAC40 | 8,224.95 | 8,257.33 | 8,211.62 | -12.48 | -0.15% | | ■ 欧洲斯托克50 | 5,919.45 | 5,940.96 | 5,910.95 | -12.34 | -0.21% | 3. 截至发稿，WTI原油跌0.37%，报56.92美元/桶。布伦特原油跌0.10%，报60.64美元/桶。 | ■ WTI原油 | 2026年2月 | 56.92 | 57.09 | 55.78 | -0.21 | -0.37% | | --- | --- | --- | --- | --- | --- | --- | | 瑶 伦敦布伦特原油 | 2026年3月 | 60.64 | 60.72 | 59.88 ...

At 7:30 a.m. ET on Wednesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening bell.For active traders, premarket trading offers a head start in spotting potential breakouts, reversals, or sharp price swings. These early moves often indicate where momentum may carry into the regular session, making premarket analysis a key part of the trading day.In the Green - Premarket GainersThe following stocks are trading hi ...

美国生物制药公司Ventyx Biosciences(VTYX.US)盘前飙升70%，报17.11美元。据华尔街日报引述消息 称，礼来就拟以超过10亿美元收购Ventyx Biosciences的交易进行深入谈判。潜在收购Ventyx将为礼来的 产品管线增加治疗炎症性肠病的药物，以及治疗帕金森等疾病的药物。此外，Ventyx的一种实验性药物 目前正在中期开发阶段，用于治疗与肥胖相关的心血管疾病。(格隆汇) ...

Ventyx Biosciences Inc. (NASDAQ:VTYX) shares are trending on Wednesday. Check out the current price of VTVX stock here. Shares of the biopharma company jumped 62.59% to $16.34 in after-hours trading on Tuesday, following reports that Indianapolis-based Eli Lilly & Co. (NYSE:LLY) is in advanced talks to acquire the company for more than $1 billion, according to The Wall Street Journal.The report, citing sources, said a deal could be announced imminently.Ventyx and Eli Lilly did not immediately respond to Ben ...